Tesamorelin Spray

Research-Documented Benefits

• Visceral Adipose Reduction — Tesamorelin is the only GHRH analog with demonstrated selective reduction of visceral adipose tissue (VAT) in controlled studies.
• Lipodystrophy Management — FDA-approved for HIV-associated lipodystrophy, with documented reductions in trunk fat without affecting subcutaneous adipose tissue.
• Cognitive Function — Research in aging populations indicates improved executive function and verbal memory, potentially via IGF-1-mediated neuroplasticity.
• Cardiovascular Markers — Studies show improvements in triglyceride levels and C-reactive protein, both associated with reduced cardiovascular risk.
• Preserved Pituitary Axis — Maintains natural GH pulsatility and somatostatin feedback, avoiding the metabolic disruptions seen with exogenous GH.

Mechanism of Action

Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoic acid group attached to the tyrosine at position 1, enhancing stability and receptor binding.

Primary Pathways

• Modified GHRH-R Agonism — The trans-3-hexenoic acid modification improves peptide stability and extends half-life while maintaining full agonist activity at the GHRH receptor.
• Selective Lipolysis — Research demonstrates preferential mobilization of visceral adipose tissue (VAT) triglycerides, with minimal effect on subcutaneous fat stores—a selectivity mechanism not fully elucidated.
• GH-Mediated IGF-1 Production — Stimulates pulsatile GH release that drives hepatic IGF-1 synthesis, activating downstream metabolic and anabolic pathways.
• Cognitive Pathway Engagement — IGF-1 elevation is hypothesized to cross the blood-brain barrier and support hippocampal neurogenesis and synaptic plasticity, potentially underlying observed cognitive benefits.

Tesamorelin's unique property of selective visceral fat reduction, combined with preserved pituitary axis feedback, makes it a distinctive research tool in metabolic and aging studies.

Research Protocol Guidelines

All protocols described are for in vitro and in vivo research purposes only. Not for human use.

Reconstitution

Reconstitute lyophilized tesamorelin with the provided diluent (sterile water). For a 2 mg vial, adding 2 mL yields 1 mg/mL. Roll gently between palms—do not shake.

Research Dosing (Published Clinical Literature)

• FDA-approved dosing (reference): 2 mg subcutaneously once daily in HIV-associated lipodystrophy trials
• Visceral fat studies: 2 mg/day SC for 26-52 weeks, with imaging assessment (CT/MRI) of visceral adipose tissue
• Cognitive studies: 2 mg/day SC for 20 weeks with neuropsychological battery testing in aged subjects

Storage

Store lyophilized form at 2-8°C (refrigerated). Reconstituted solution at 2-8°C, use within 14 days. Tesamorelin is sensitive to heat; never freeze reconstituted solution.

Safety & Handling Information

For research use only. Not intended for human or veterinary diagnostic or therapeutic use.

Storage Requirements

• Lyophilized: 2-8°C (refrigerated, do not freeze)
• Reconstituted: 2-8°C, use within 14 days
• Temperature-sensitive; discard if exposed to temperatures above 25°C for extended periods

Clinical Safety Data

Tesamorelin has extensive clinical safety data as an FDA-approved agent (Egrifta). Phase III trials demonstrated a generally well-tolerated profile with injection site reactions as the primary adverse event.

Known Considerations

• Anti-tesamorelin antibodies develop in approximately 50% of subjects in long-term studies, though clinical significance is unclear
• Fluid retention and peripheral edema reported in some subjects
• IGF-1 monitoring recommended in chronic studies due to theoretical neoplasia risk
• Discontinuation leads to re-accumulation of visceral fat—effects are not permanent

Handling

Standard laboratory PPE. Tesamorelin is temperature-sensitive and should be transported and stored under refrigerated conditions at all times.

Frequently Asked Questions